IDH2 and central nervous system cancer: GBM in elderly patients also seems to be biologically more aggressive, with a very low incidence of favorable prognostic markers such as IDH mutations and the glioma cytosine–phosphate–guanine island methylator phenotype, although MGMT status does not seem to vary with age [24].